Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.42 |
| ▸ | KDM4A | O75164 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.42 |
| ▸ | TET3 | O43151 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL2905545 | 1.00 | OR51E2 (0.82) | OR51E2SMN1; SMN2TET2KDM4AKDM4C | |
| Acetone SCHEMBL5970433 | 1.00 | OR51E2 (0.82) | OR51E2SMN1; SMN2TET2KDM4AKDM4C | |
| Acetone SCHEMBL9414004 | 0.97 | OR51E2 (0.78) | OR51E2SMN1; SMN2TET2KDM4AKDM4C | |
| Acetic Acid SCHEMBL6399948 | 0.94 | OR51E2 (0.82) | OR51E2SMN1; SMN2TET2KDM4AKDM4C | |
| Acetic Acid SCHEMBL9450190 | 0.94 | OR51E2 (0.82) | OR51E2SMN1; SMN2TET2KDM4AKDM4C | |
| SCHEMBL1765577 | 0.91 | OR51E2 (1.00) | OR51E2SMN1; SMN2TET2KDM4AKDM4C | |
| Water SCHEMBL10757023 | 0.91 | — | — | |
| SCHEMBL38462 | 0.91 | — | — | |
| SCHEMBL2905876 | 0.91 | — | — | |
| Water SCHEMBL21753470 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20210047284-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200247774-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200024248-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2020-01-23 | — | — | US | disclosed |
| US-20190233387-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| EP-2963031-B1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2019-02-06 | — | — | EP | disclosed |
| US-20190031637-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180208572-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2018-07-26 | — | — | US | disclosed |
| US-9957246-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ZYNERBA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9695143-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ZYNERBA PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170088533-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. | 2017-03-30 | — | — | US | disclosed |
| EP-2963031-A2 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | Zynerba Pharmaceuticals, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150218121-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2215071-B1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2215071-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | AllTranz Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009073633-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208572-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OR51E2 3618/4885SMN1; SMN2 2009/4885TET2 2295/4885 |
| US-20200247774-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OR51E2 3618/4885SMN1; SMN2 2009/4885TET2 2295/4885 |
| US-20190233387-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OR51E2 3618/4885SMN1; SMN2 2009/4885TET2 2295/4885 |
| US-20200024248-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OR51E2 3618/4885SMN1; SMN2 2009/4885TET2 2295/4885 |
| US-20150218121-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OR51E2 3618/4885SMN1; SMN2 2009/4885TET2 2295/4885 |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OR51E2 3896/4885SMN1; SMN2 2426/4885TET2 2388/4885 |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OR51E2 3618/4885SMN1; SMN2 2009/4885TET2 2295/4885 |
| US-20190031637-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OR51E2 3618/4885SMN1; SMN2 2009/4885TET2 2295/4885 |
| US-20170088533-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OR51E2 3618/4885SMN1; SMN2 2009/4885TET2 2295/4885 |
| US-20210047284-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OR51E2 3618/4885SMN1; SMN2 2009/4885TET2 2295/4885 |
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OR51E2 3896/4885SMN1; SMN2 2426/4885TET2 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.